Two global pharmaceutical firms - Hilleman Laboratories and Gotovax AB - Tuesday joined hands to develop affordable oral cholera vaccine. 'Our partnership with Gotovax AB is carefully aligned to Hilleman Laboratories' core philosophy of addressing unmet health needs of the underprivileged by developing accessible and innovative vaccines which are affordable' Hilleman Laboratories' chief executive officer Davinder Gill said. (Read: Wash hands the right way; prevent diseases like cholera typhoid and gastroenteritis) Hilleman Laboratories is a Merck & Co and UK-based Wellcome Trust joint venture while Gotovax AB is a bio-pharmaceutical firm. 'There is an urgent need for highly effective and